A study shows that a drug that is among the best-selling diabetes mellitus, is beneficial to a wider range of patients than previously indicated, enhancing the potential of this product.
It is related to the drug “Farxiga” produced by the British pharmaceutical company “AstraZeneca”.
Farxiga has so far been approved for patients with diabetes or kidney disease to prevent heart failure, as well as for those already suffering from insufficiency due to low levels of blood being pumped out every time the heart contracts.
The latest findings show that the drug can also work on patients with heart failure who have higher levels of blood pumped with each heartbeat.
The British pharmaceutical giant had already revealed high-level results last May showing that this study on Farxiga had met its primary end point. Full details of the study were presented at the European Society of Cardiology conference in Barcelona, Spain, on Saturday.
AstraZeneca said it is submitting requests to the US Food and Drug Administration for extended use of the drug.
#Diabetes #medication #wider #range #patients